Overcoming challenges in ADC discovery and development
Supported by a strong bioconugation process, our team delivers the expertise, equipment, and capabilities you need to successfully carry your ADC candidate from early discovery through development and beyond.
Proof of Concept
We offer a customised service for your early stage ADC Development. During initial proof of concept (PoC), we can help you assess different payload, linker, and conjugation strategies to develop an ADC tailored to your needs. Whether you have a proprietary antibody/target or payload we can design an ADC that is right for you. We have worked with various targeting molecules, linkers, and toxins to overcome challenges and deliver superior solutions to our customers.
Our Proof of Concept services include:
- Various conjugation approaches, including cysteine, lysine, and enzymatic
- Generation of different DAR conjugates
- Availability of multiple toxin classes
- Cleavable and non-cleavable linkers
- Platform or customised analytics and certification
- Availability of model antibodies
- Linker design for novel payloads
- Milligram to hundreds of milligrams scale
- TFF, chromatographic and activated carbon purification methods as required
- Certified ADCs: minimally DAR, monomer, concentration, and residual toxin
- Additional analysis, including: endotoxin, bioburden, mass spectrometry – DAR, mass confirmation, plasma stability, Maurice CE-SDS and icIEF, internalisation and in vitro potency testing
Process development and scale up
We have a proven track record in developing GMP-ready processes for our customers’ ADC programmes and draw upon our experience in process and analytical development to design an approach that simultaneously maximises quality, efficiency, and output. We support large-scale tox batch preparation and certification for preclinical animal studies, bringing your ADC from the milligram to multi-gram scale. ... Read more
Our ‘right-first-time’ approach to process development includes:
- QbD approach exploiting experience, DOE, and OFAT methods
- Optimisation of reactive stages, including chemical and enzymatic
- Development of supporting purification methods
- Phase-appropriate robustness studies
- Process characterisation Read less
“ADCs are well established and proven in the oncology space, and now other bioconjugate modalities are being developed for an increasing number of therapeutic classes. Our vast experience working with different antibodies, linkers, conjugation approaches and payload types enables us to advise our customers in choosing a successful combination that will meet their objectives. Our goal is to empower our customers to streamline their products’ path to market in order to help all bioconjugates reach more widespread availability and use.
” Colin McKee | Head of Technical Services
Related Services
Related Content
